Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CYCCNASDAQ:JBIONASDAQ:LSBNASDAQ:NTBL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYCCCyclacel Pharmaceuticals$0.35-4.3%$2.16$0.25▼$39.84$8.21M0.24419,456 shs747,083 shsJBIOJade Biosciences$9.25-12.0%$0.00$6.57▼$105.00$8.83M0.93477,362 shs243,176 shsLSBLakeShore Biopharma$0.93-3.1%$1.10$0.87▼$8.60$8.93M0.5921,531 shs31,381 shsNTBLNotable Labs$0.25$0.33$0.22▼$4.24$2.24M0.981.01 million shs2.11 million shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYCCCyclacel Pharmaceuticals-4.30%+3.64%-78.41%-92.69%-98.86%JBIOJade Biosciences-11.99%-1.70%+924,999,900.00%+924,999,900.00%+924,999,900.00%LSBLakeShore Biopharma-3.12%-4.12%-11.42%-62.95%+92,999,900.00%NTBLNotable Labs0.00%0.00%0.00%0.00%-60.98%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYCCCyclacel Pharmaceuticals0.5723 of 5 stars0.03.00.00.02.21.70.0JBIOJade Biosciences2.449 of 5 stars3.50.00.00.02.71.70.6LSBLakeShore Biopharma1.0912 of 5 stars0.03.00.00.03.80.80.6NTBLNotable LabsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYCCCyclacel Pharmaceuticals 2.00HoldN/AN/AJBIOJade Biosciences 3.00Buy$14.0051.35% UpsideLSBLakeShore Biopharma 0.00N/AN/AN/ANTBLNotable Labs 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest NTBL, LSB, JBIO, and CYCC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2025JBIOJade BiosciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$14.00(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYCCCyclacel Pharmaceuticals$40K196.33N/AN/A($3.93) per share-0.09JBIOJade BiosciencesN/AN/AN/AN/A$92.88 per shareN/ALSBLakeShore Biopharma$80.82M0.11N/AN/A$8.86 per share0.10NTBLNotable Labs$313K7.14N/AN/A$6.81 per share0.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYCCCyclacel Pharmaceuticals-$11.21M-$56.00N/A∞N/A-18,150.00%-3,648.09%-155.99%7/1/2025 (Estimated)JBIOJade Biosciences-$69.63M-$59.650.00∞N/AN/A-60.01%-54.32%N/ALSBLakeShore Biopharma-$61.09MN/A0.00∞N/AN/AN/AN/A8/18/2025 (Estimated)NTBLNotable Labs-$11.26MN/A0.00∞N/AN/A-80.81%-62.86%N/ALatest NTBL, LSB, JBIO, and CYCC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/2/2025Q4 2024CYCCCyclacel Pharmaceuticals-$4.64-$5.28-$0.64-$0.33$0.01 million$0.01 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYCCCyclacel PharmaceuticalsN/AN/AN/AN/AN/AJBIOJade BiosciencesN/AN/AN/AN/AN/ALSBLakeShore BiopharmaN/AN/AN/AN/AN/ANTBLNotable LabsN/AN/AN/AN/AN/ALatest NTBL, LSB, JBIO, and CYCC DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/28/2025CYCCCyclacel Pharmaceuticals$2.404/29/20254/29/20255/1/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYCCCyclacel PharmaceuticalsN/A5.605.60JBIOJade BiosciencesN/A32.0132.01LSBLakeShore Biopharma0.131.170.90NTBLNotable Labs0.032.772.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYCCCyclacel Pharmaceuticals23.58%JBIOJade BiosciencesN/ALSBLakeShore Biopharma52.64%NTBLNotable Labs70.48%Insider OwnershipCompanyInsider OwnershipCYCCCyclacel Pharmaceuticals96.90%JBIOJade Biosciences24.90%LSBLakeShore BiopharmaN/ANTBLNotable Labs1.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYCCCyclacel Pharmaceuticals1422.45 million696,000OptionableJBIOJade Biosciences20840,000632,000N/ALSBLakeShore Biopharma7739.31 millionN/AN/ANTBLNotable Labs409.02 million9.54 millionNo DataNTBL, LSB, JBIO, and CYCC HeadlinesRecent News About These CompaniesNotable Labs, Ltd. (NTBLQ)February 13, 2025 | finance.yahoo.comWhat Factors Have Led to Notable Labs Ltd (NTBL) Stock Trading -93.03% Below Its 52-Week High?October 22, 2024 | bovnews.comBNotable Labs Ltd (NTBL) Stock: Greater Than Its Current Valuation?October 18, 2024 | bovnews.comBNotable Labs files for bankruptcy, ending ambitions for Boehringer cancer drugOctober 16, 2024 | fiercebiotech.comFNotable Labs Pauses Implementation of Cancer Drug Volasertib Study, Announces LayoffsSeptember 20, 2024 | marketwatch.comNotable Labs (NTBL) was downgraded to a Hold Rating at JMP SecuritiesSeptember 20, 2024 | markets.businessinsider.comNotable Labs to Present Data on September 4th at SOHO 2024August 29, 2024 | globenewswire.comNotable Labs Announces CEO TransitionAugust 27, 2024 | finance.yahoo.comNTBL Stock Earnings: Notable Labs Misses EPS for Q2 2024August 16, 2024 | investorplace.comLA’s best burrito is a lab-engineered marvelAugust 15, 2024 | msn.comNotable Labs: Q2 Earnings SnapshotAugust 15, 2024 | sfgate.comNotable Labs, Ltd. (NTBL)July 26, 2024 | finance.yahoo.comIt’s Better to Hope for Prosperity than Become Adversary: Notable Labs Ltd (NTBL) StockJuly 25, 2024 | bovnews.comBNotable Labs Cleared by FDA to Begin Phase II Trial of Volasertib in AMLJuly 24, 2024 | precisionmedicineonline.comPNotable Labs Receives FDA Clearance to Proceed Further with Volasertib Phase 2 StudyJuly 24, 2024 | globenewswire.comNPC Labs raises $18M to bring mainstream games to Web3July 22, 2024 | venturebeat.comVBears are Losing Control Over Notable Labs (NTBL), Here's Why It's a 'Buy' NowMay 24, 2024 | zacks.comOppenheimer raised the price target for the Notable Labs Ltd (NASDAQ:NTBL) stock to “”a Perform””May 24, 2024 | bovnews.comBNTBL Stock Earnings: Notable Labs Misses EPS for Q1 2024May 16, 2024 | investorplace.comBuy Rating Affirmed for Notable Labs Amid Promising Drug Program and Robust PPMP PlatformMay 16, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNTBL, LSB, JBIO, and CYCC Company DescriptionsCyclacel Pharmaceuticals NASDAQ:CYCC$0.35 -0.02 (-4.30%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$0.35 +0.00 (+0.34%) As of 04:54 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.Jade Biosciences NASDAQ:JBIO$9.25 -1.26 (-11.99%) As of 06/26/2025 04:00 PM EasternAerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.LakeShore Biopharma NASDAQ:LSB$0.93 -0.03 (-3.13%) Closing price 06/26/2025 03:57 PM EasternExtended Trading$0.92 -0.01 (-1.51%) As of 06/26/2025 05:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LakeShore Biopharma Co., Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People's Republic of China and Other Countries or Regions. The company was founded by Yi Zhang on November 16, 2020 and is headquartered in Beijing, China.Notable Labs NASDAQ:NTBLNotable Labs, Ltd., a clinical-stage platform therapeutics company, develops predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient will clinically respond to their actual treatment. Its PPMP is designed to identify and select clinically responsive patients prior to their treatment and enables fast-track therapeutic development in this patient population. The company's pipeline includes Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor to induce cell cycle arrest and apoptosis in various cancer cells; and Fosciclopirox, a pro-drug of ciclopirox for acute myeloid leukemia. Notable Labs, Ltd. was incorporated in 2014 and is headquartered in Foster City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside Is IBM’s AI Transformation Powering a Sustained Rally? Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst Amazon: Why Some Are Growing Bearish, and Why They’re Wrong ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside Astera Labs: AI Infrastructure Play With Significant Growth Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
